Skip to main content

Witness for the Prosecution

SPOILER ALERT. I'm about to reference the ending of a venerable short story and a movie adaptation from the Golden Age of Hollywood. If you wish to read or view either of these in innocence, don't proceed further.

Old Hollywood had a rule that the bad guys never win. The evildoers always get their comeuppance. After all, if people wanted to see evil prosper, they didn't have to go to the cinema for that, they could just stick with the morning newspaper.

Anyway, the rule resulted in innovative re-writes to certain adapted literary works. This may never have been more jarring than in the case of Witness for the Prosecution, a 1925 Agatha Christie short story that had a complicated publication history over the next three decades and that became a movie only in 1957.


The basic plot of the short story is that of a criminal trial portrayed through the eyes of a sympathetic defense attorney, played in the movie by Charles Laughton. Laughton's character agrees to defend a man charged with the murder of a wealthy elderly woman.

The defendant is played by Tyrone Power in the movie. His wife, Christine, by Marlene Dietrich.  [Those three names make up about as glittering a cast list as the era could offer.] At any rate, the defendant persuades his barrister (and the innocent audience) of his innocence, but whether the lawyer will be able to persuade a jury seems to turn on whether Christine will give alibi evidence.

Alas, Christine switches sides. She prepares to give contrary evidence as a "Witness for the Prosecution," hence the title.

In another twist, the barrister uncovers evidence that will allow for a devastating cross-examination of Christine.

The in-court show-down then plays out. Prosecution presents its surprise witness; Laughton devastates her credibility; jury brings in a verdict of not guilty. THEN comes the twist ending.

Dietrich confides in the barrister that she herself planted the evidence that he found and used to impeach her credibility, and she had gone to the prosecution planning to be discredited.

She couldn't take the chance of an honest unrigged trial, she says.

"Why, because you knew your husband was innocent."

"No, because I knew he was guilty."

THOSE words are the end of the story, and they work wonderfully, because Christie had been successful in luring us into the contrary conviction.

But as I've noted, Hollywood in the 1950s could not have a story end with a man getting away with murder. So there is a coda in which the barrister expresses his outrage, then the newly-acquitted defendant enters the discussion and tells Christine that he is leaving her for a younger woman. Christine stabs him with a letter opener (which had been an exhibit in the trial) and kills him.

The barrister immediately decides that he will defend Christine against the inevitable charge of murder, and the credits finally roll.

I really wish the creative people involved had found a way to evade the Code and make this movie without the Coda.


  1. This comment has been removed by a blog administrator.


Post a Comment

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.

We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

England as a Raft?

In a lecture delivered in 1880, William James asked rhetorically, "Would England ... be the drifting raft she is now in European affairs if a Frederic the Great had inherited her throne instead of a Victoria, and if Messrs Bentham, Mill, Cobden, and Bright had all been born in Prussia?"

Beneath that, in a collection of such lectures later published under James' direction, was placed the footnote, "The reader will remember when this was written."

The suggestion of the bit about Bentham, Mill, etc. is that the utilitarians as a school helped render England ineffective as a European power, a drifting raft.

The footnote was added in 1897. So either James is suggesting that the baleful influence of Bentham, Mill etc wore off in the meantime or that he had over-estimated it.

Let's unpack this a bit.  What was happening in the period before 1880 that made England seem a drifting raft in European affairs, to a friendly though foreign observer (to the older brother…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…